Woodline Partners’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.24M | Sell |
300,419
-299,903
| -50% | -$5.23M | 0.03% | 549 |
|
|
2025
Q1 | $7.55M | Sell |
600,322
-518,961
| -46% | -$6.53M | 0.05% | 411 |
|
|
2024
Q4 | $11.8M | Buy |
1,119,283
+133,276
| +14% | +$1.41M | 0.08% | 307 |
|
|
2024
Q3 | $14.3M | Buy |
986,007
+704,863
| +251% | +$10.2M | 0.12% | 233 |
|
|
2024
Q2 | $2.39M | Sell |
281,144
-120,644
| -30% | -$1.03M | 0.02% | 403 |
|
|
2024
Q1 | $4.11M | Sell |
401,788
-259,626
| -39% | -$2.65M | 0.04% | 378 |
|
|
2023
Q4 | $3.62M | Sell |
661,414
-185,640
| -22% | -$1.02M | 0.04% | 341 |
|
|
2023
Q3 | $3.2M | Buy |
847,054
+176,967
| +26% | +$669K | 0.04% | 357 |
|
|
2023
Q2 | $4.49M | Buy |
670,087
+70,087
| +12% | +$470K | 0.05% | 306 |
|
|
2023
Q1 | $3.91M | Sell |
600,000
-661,307
| -52% | -$4.31M | 0.05% | 327 |
|
|
2022
Q4 | $10.8M | Buy |
1,261,307
+448,408
| +55% | +$3.82M | 0.14% | 193 |
|
|
2022
Q3 | $4.29M | Buy |
+812,899
| New | +$4.29M | 0.06% | 329 |
|
|
2022
Q2 | – | Sell |
-83,571
| Closed | -$293K | – | 880 |
|
|
2022
Q1 | $293K | Sell |
83,571
-410,324
| -83% | -$1.44M | ﹤0.01% | 534 |
|
|
2021
Q4 | $3.29M | Buy |
493,895
+68,634
| +16% | +$457K | 0.05% | 343 |
|
|
2021
Q3 | $4.24M | Buy |
425,261
+47,630
| +13% | +$475K | 0.07% | 277 |
|
|
2021
Q2 | $11.7M | Buy |
377,631
+170,948
| +83% | +$5.28M | 0.22% | 119 |
|
|
2021
Q1 | $9.02M | Sell |
206,683
-8,853
| -4% | -$386K | 0.2% | 129 |
|
|
2020
Q4 | $9.99M | Buy |
+215,536
| New | +$9.99M | 0.26% | 116 |
|